FOLLOWUS
Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression (GLAD Study): A Randomized Double-Blind Placebo-Controlled Study
- Chinese Journal of Integrative Medicine Vol. 29, Issue 3, Pages: 195-204(2023)
- Affiliations：
1.Department of Cardiovascular Disease, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing(100091), China
2.National Clinical Research Center for Chinese Medicine Cardiology, Beijing(100091), China
3.Department of Cardiovascular Disease, Guangdong Provincial People's Hospital, Guangzhou (510055), China
4.Department of Cardiovascular Disease, Shanghai Tongji Hospital, Shanghai(200065), China
5.Department of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing(100037), China
6.Department of Cardiovascular Disease, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing(100020), China
7.Department of Cardiovascular Disease, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun (130021), China
8.Department of Cardiovascular Disease, People's Hospital of Peking University, Beijing(100044), China
- Author bio：
Prof. CHEN Ke-ji, E-mail: kjchenvip@163.com
- Funds：
DOI：10.1007/s11655-022-3688-3
CLC：Published：2023-03，
Published Online：27 October 2022，
Accepted：22 July 2022
Scan for full text
WANG Cheng-long, HUAN Na, WANG Pei-li, et al. Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression (GLAD Study): A Randomized Double-Blind Placebo-Controlled Study. [J]. Chinese Journal of Integrative Medicine 29(3):195-204(2023)
WANG Cheng-long, HUAN Na, WANG Pei-li, et al. Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression (GLAD Study): A Randomized Double-Blind Placebo-Controlled Study. [J]. Chinese Journal of Integrative Medicine 29(3):195-204(2023) DOI： 10.1007/s11655-022-3688-3.
摘要
目的:
2
评价冠心丹参滴丸 (GXDS) 治疗冠心病患者经皮冠状动脉介入治疗 (PCI) 后抑郁或焦虑的疗效和安全性.
方法:
2
采用随机数表法将200名参与者随机分为实验组 (GSDX
100例) 和对照组 (100名) . GXDS和对照组分别给予GXDS和安慰剂
每次0.4 g
每天3次
持续12周. 主要治疗指标为PHQ-9、GAD-7和SAQ) 的得分. 次要指标包括SF-12评分、首次发病时间和主要不良心血管事件 (MACEs) 发生率.
结果:
2
在全分析集 (200例) 分析中
GXDS组治疗后PHQ-9和GAD-7评分显著低于对照组 (
P
<
0.05) . 与基线值相比
实验组和对照组的PHQ-9总分分别下降3.97和1.18. 两组之间的校正平均差为-2.78 (95% CI: -3.47
-2.10;
P
<
0.001) . GXDS组的GAD-7总分与基线水平相比下降了3.48%
而对照组下降了1.13%. 两组间的校正平均值差为-2.35 (95% CI: -2.95
-1.76;
P
<
0.0001)
GXDS组内皮素和hs-CRP水平显著高于对照组
两组之间的差异具有统计学意义 (
P
<
0.05) . 本研究观察到3例不良事件
未发生严重不良事件.
结论:
2
GXDS对冠心病患者PCI后抑郁或焦虑的治疗有效
可以显著缓解抑郁和焦虑
缓解心绞痛症状
提高生活质量. (注册号: ChiCTR1800014291)
Abstract
Objective:
2
To assess the efficacy and safety of Guanxin Danshen Dripping Pills (GXDS) in the treatment of depression or anxiety in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).
Methods:
2
From September 2017 to June 2019
200 CHD patients after PCI with depression and anxiety were included and randomly divided into GXDS (100 cases) and placebo control groups (100 cases) by block randomization and a random number table. Patients in the GXDS and control groups were given GXDS and placebo
respectively
0.4 g each time
3 times daily for 12 weeks. The primary outcomes were scores of Patient Health Questionnaire-9 (PHQ-9)
Generalized Anxiety Scale (GAD-7) and the Seattle Angina Pectoris Scale (SAQ). The secondary outcomes included 12 Health Survey Summary Form (SF-12) scores and the first onset time and incidence of major adverse cardiovascular events (MACEs). Other indices including blood pressure
blood lipids
microcirculation and inflammatory-related indices
etc. were monitored at baseline
week 4
and week 12.
Results:
2
In the full analysis set (200 cases)
after treatment
the PHQ-9 and GAD-7 scores in the GXDS group were considerably lower than those in the control group (
P
<
0.05). Compared with the baseline
the total PHQ-9 scores of the experimental and control groups decreased by 3.97 and 1.18
respectively. The corrected mean difference between the two groups was –2.78 (95% CI: –3.47
–2.10;
P
<
0.001). The total GAD-7 score in the GXDS group decreased by 3.48% compared with the baseline level
while that of the placebo group decreased by 1.13%. The corrected mean difference between the two groups was –2.35 (95% CI: –2.95
–1.76;
P
<
0.001). The degree of improvement in SAQ score
SF-12 score
endothelin and high-sensitive C-reactive protein levels in the GXDS group were substantially superior than those in the placebo group
and the differences between the two groups were statistically significant (
P
<
0.05). Similar results were obtained in the per protocol population analysis of 177 patients. Three cases of MACES were reported in this study (1 in the GXDS group and 2 in the placebo group)
and no serious adverse events occurred.
Conclusions:
2
GXDS can significantly alleviate depression and anxiety
relieve symptoms of angina
and improve quality of life in patients with CHD after PCI. (Registration No. ChiCTR1800014291)
关键词
冠心病经皮冠状动脉介入治疗抑郁和焦虑状态随机对照试验临床疗效
Keywords
Chinese medicinecoronary heart diseasepercutaneous coronary interventiondepression and anxiety stateclinical efficacy
references
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation 2022;145:e153-e639.
Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:1827-1845.
Olsen SJ, Schirmer H, Wilsgaard T, Bønaa KH, Hanssen TA. Cardiac rehabilitation and symptoms of anxiety and depression after percutaneous coronary intervention. Eur J Prev Cardiol 2018;25:1017-1025.
Pogosova N, Kotseva K, De Bacquer D, von Känel R, De Smedt D, Bruthans J, et al. EUROASPIRE Investigators. Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: results from the EUROASPIRE Ⅳ survey. a registry from the European Society of Cardiology. Eur J Prev Cardiol 2017;24:1371-1380.
De Bacquer D, De Smedt D, Kotseva K, Jennings C, Wood D, Rydén L, et al. Incidence of cardiovascular events in patients with stabilized coronary heart disease:the EUROASPIRE Ⅳ follow-up study. Eur J Epidemiol 2019;34:247-258.
Carney RM, Freedland KE. Depression and coronary heart disease. Nat Rev Cardiol 2017;14:145-155.
Konstantinides SV, Meyer G. The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2019;40:3453-3455.
Han XJ, Li H, Liu CB, Luo ZR, Wang QL, Mou FF, et al. Guanxin Danshen Formulation improved the effect of mesenchymal stem cells transplantation for the treatment of myocardial infarction probably via enhancing the engraftment. Life Sci 2019;233:116740.
Liu R, Jiang LJ, Yang Y, Wang CC, Tong X, Xu WM, et al. Study on syndrome differentiation strategy of phlegm and blood stasis syndromes of coronary heart disease based on expert consultation on medical cases. Ann Palliat Med 2021;10:9940-9952.
Deng X, Xing X, Sun G, Xu X, Wu H, Li G, et al. Guanxin Danshen Formulation protects against myocardial ischemia reperfusion injury-induced left ventricular remodeling by upregulating estrogen receptor β. Front Pharmacol 2017;8:777.
Yao H, Huang X, Li S, Wu Y, Lin X, Shi P. Simultaneous determination of eight phenolic acids, five saponins and four tanshinones for quality control of compound preparations containing danshen-sanqi herb-pair by HPLC-DAD. Pharmacogn Mag 2017;13:64-75.
Xie W, Meng X, Zhai Y, Ye T, Zhou P, Nan F, et al. Antidepressant-like effects of the Guanxin Danshen formula via mediation of the CaMKⅡ-CREB-BDNF signalling pathway in chronic unpredictable mild stress-induced depressive rats. Ann Transl Med 2019;7:564.
Task FM, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
Bredy C, Ministeri M, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes 2018;4:51-58.
Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel Ⅲ guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014;311:1416-1423.
Costantini L, Pasquarella C, Odone A, Colucci ME, Costanza A, Serafini G, et al. Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9):a systematic review. J Affect Disord 2021;279:473-483.
Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Härter M, Schramm E, et al. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord 2020;265:395-401.
Burton D, King A, Bartley J, Petrie KJ, Broadbent E. The surgical anxiety questionnaire (SAQ): development and validation. Psychol Health 2019;34:129-146.
Richards DA, Hill JJ, Gask L, Lovell K, Chew-Graham C, Bower P, et al. Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trial. BMJ 2013;347:f4913.
Cowie A, Buckley J, Doherty P, Furze G, Hayward J, Hinton S, et al. Standards and core components for cardiovascular disease prevention and rehabilitation. Heart 2019;105:510-515.
Zhou Y, Xu J, Rief W. Are comparisons of mental disorders between Chinese and German students possible? An examination of measurement invariance for the PHQ-15, PHQ-9 and GAD-7. BMC Psychiatry 2020;20:480.
Lawal OA, Awosoga O, Santana MJ, James MT, Southern DA, Wilton SB, et al. Psychometric evaluation of a Canadian version of the Seattle Angina Questionnaire(SAQ-CAN). Health Qual Life Outcomes 2020;18:377.
Li X, Yang S, Wang Y, Yang B, Zhang J. Effects of a transtheoretical model-based intervention and motivational interviewing on the management of depression in hospitalized patients with coronary heart disease: a randomized controlled trial. BMC Public Health 2020;20:420.
Yang L, Korhonen K, Moustgaard H, Silventoinen K, Martikainen P. Pre-existing depression predicts survival in cardiovascular disease and cancer. J Epidemiol Community Health 2018;72:617-622.
Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;30:2047487320913379.
Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013;75:335-349.
Tatoulis J, Psychosocial Risk Factors Expert Working Group of the National Heart Foundation of Australia. The rationale for depression screening in patients with coronary heart disease. On behalf of the Psychosocial Risk Factors Expert Working Group of the National Heart Foundation of Australia. J Psychosom Res 2014;76:172-173.
Levine GN, Lange RA, Bairey-Merz CN, Davidson RJ, Jamerson K, Mehta PK, et al. Meditation and cardiovascular risk reduction: a scientific statement from the American Heart Association. J Am Heart Assoc 2017;6:e002218.
Harshfield EL, Pennells L, Schwartz JE, Willeit P, Kaptoge S, Bell S, et al. Association between depressive symptoms and incident cardiovascular diseases. JAMA 2020;324:2396-2405.
Wu Y, Zhu B, Chen Z, Duan J, Luo A, Yang L, et al. New insights into the comorbidity of coronary heart disease and depression. Curr Probl Cardiol 2021;46:100413.
Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41:1687-1696.
Pimple P, Hammadah M, Wilmot K, Ramadan R, Al Mheid I, Levantsevych O, et al. Chest pain and mental stress-induced myocardial ischemia: sex differences. Am J Med 2018;131:540-547.e1.
Lera L, Márquez C, Saguez R, Moya MO, Angel B, Albala C. Quality of life of older people with depression and dependence: validity of the SF-12 (Short Form Health Survey) Questionnaire. Rev Med Chil 2021;149:1292-1301.
Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisle VC, Arthurs E, et al. Does evidence support the American Heart Association's recommendation to screen patients for depression in cardiovascular care? An updated systematic review. PLoS One 2013;8:e52654.
Lavoie KL, Paine NJ, Pelletier R, Arsenault A, Diodati JG, Campbell TS, et al. Relationship between antidepressant therapy and risk for cardiovascular events in patients with and without cardiovascular disease. Health Psychol 2018;37:989-999.
Er L. Clinical trial of Guanxin Danshen Dripping Pills combined with simvastatin tablets in the treatment of thecoronary heart disease. Chin J Clin Pharmacol (Chin) 2018;34:14-17.
Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482-489.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016;16:22-34.
Barton M, Yanagisawa M. Endothelin: 30 years from discovery to therapy. Hypertension 2019;74:1232-1265.
Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, et al. Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases:a systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm 2022;2022:8732360.
Wang YL, Zhou CR, Yu TL, Zhao F. Correlation between changes in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the treatment of coronary heart disease. J Healthc Eng 2021;2021:8476592.
Zhao G, Zhang H, Wang Y, Gao X, Liu H, Liu W. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure. Hellenic J Cardiol 2020;61:99-102.
Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk:moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129-2138.
Kumar V, Sharma AK, Kumar T, Nath RK. Large intracoronary thrombus and its management during primary PCI. Indian Heart J 2020;72:508-516.
Qu H, Guo M, ChaiI H, Liang F, Gao ZY, Shi DZ. Effects of Guanxin Danshen Dripping Pill (GXDS) on blood stasis syndrome scores and levels of serum associated adhesion factors in chronic stable angina patients with blood stasis syndrome. J Tradit Chin Med (Chin) 2017;58:394-397.
Liu WW, Xue XJ, Luo XY, Ji WM, Wang XB, Ge YS, et al. Effects of Guanxin Danshen Dripping Pills on the platelet activation in the elderly patients with unstable angina pectoris of qi deficiency and blood stasis syndrome: a double-blind, placebo controlled study. J Tradit Chin Med(Chin) 2020;61:1339-1342.
0
Views
9
Downloads
0
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
